# Access Medical Ventures

> Access Medical Ventures is a VC fund backing Health Care and Manufacturing. See 5 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Tel Aviv, Israel
- Total investments: 5
- Last investment: Jun 2025
- Lead investor: 40%
- Last updated: Aug 2026
- Website: http://accessmv.com

Access Medical Ventures is a U.S based venture capital fund that focuses specifically on investing and advancing medical device start-ups. AMV’s primary interest is investing in interventional and therapeutic medical device start-ups, along with the variety of all the medical disciplines.

## Contacts

5 contacts available for Access Medical Ventures. Shizune tracks 1 team members at Access Medical Ventures. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/access-medical-ventures?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 1 | 20% |
| Manufacturing | 1 | 20% |
| Medical Device | 1 | 20% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 2 | 40% |
| Series D | 1 | 20% |
| Funding Round | 1 | 20% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Michael Tal | Partner | 4 | https://shizune.co/investors/profile/michael-tal |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Automate AI | Automate AI Medical is reimagining the future of healthcare with intelligent, personalized, and proactive wellness solutions—powered by cutting-edge artificial intelligence.Our platform combines real-time health monitoring, predictive analytics, and conversational AI to deliver a seamless healthcare experience tailored to each individual. Whetheryou’re a patient managing chronic conditions, a provider seeking smarter diagnostics, or a researcher optimizing clinical insights, Automate AI Medical empowers you with actionable, data-driven intelligence.We serve: • Patients – with AI wellness companions and 24/7 health monitoring • Healthcare Providers – with advanced diagnostic tools and intelligent alerts • Researchers – with scalable analytics and anomaly detection • Pharma & Life Sciences – with AI models that accelerate drug discovery and trialsCore Features ✓ Real-time vitals dashboard ✓ Predictive health modeling ✓ Intelligent chat assistants ✓ Seamless EHR/data integrations ✓ HIPAA-compliant infrastructureAutomate AI Medical makes healthcare more human—by letting AI handle the complexity, so you can focus on care, prevention, and peace of mind.Join us as we reshape modern wellness. Contact us to explore careers, our platform, discuss partnerships, pilots, and early access opportunities. | $2M | Series A | Jun 20, 2025 |  |
| CartiHeal | CartiHeal, a privately held medical device company headquartered in Israel, is a pioneer in the field of cartilage regeneration. Cartilage injuries affect millions of patients around the world, and characteristically cause severe pain and disability. Hyaline cartilage has a very limited ability to heal once damaged. Research indicates that injuriesto joint cartilage, if left untreated, may lead to progressive joint changes and early onset of osteoarthritis. The need for a simple, well-tolerated and effective solution for cartilage repair and regeneration represents one of medicine’s most challenging unmet needs. CartiHeal's flagship Agili-C™ implant represents a significant medical breakthrough. This implant has shown to promote regeneration of true hyaline cartilage and its subchondral bone, simultaneously without the use of cells, growth factors or other exogenous agents. The cell-free implant is inserted arthroscopically or via a minimally-invasive approach. |  |  | Oct 29, 2013 |  |
| CartiHeal | CartiHeal, a privately held medical device company headquartered in Israel, is a pioneer in the field of cartilage regeneration. Cartilage injuries affect millions of patients around the world, and characteristically cause severe pain and disability. Hyaline cartilage has a very limited ability to heal once damaged. Research indicates that injuriesto joint cartilage, if left untreated, may lead to progressive joint changes and early onset of osteoarthritis. The need for a simple, well-tolerated and effective solution for cartilage repair and regeneration represents one of medicine’s most challenging unmet needs. CartiHeal's flagship Agili-C™ implant represents a significant medical breakthrough. This implant has shown to promote regeneration of true hyaline cartilage and its subchondral bone, simultaneously without the use of cells, growth factors or other exogenous agents. The cell-free implant is inserted arthroscopically or via a minimally-invasive approach. |  |  | Jul 09, 2012 |  |
| CartiHeal | CartiHeal, a privately held medical device company headquartered in Israel, is a pioneer in the field of cartilage regeneration. Cartilage injuries affect millions of patients around the world, and characteristically cause severe pain and disability. Hyaline cartilage has a very limited ability to heal once damaged. Research indicates that injuriesto joint cartilage, if left untreated, may lead to progressive joint changes and early onset of osteoarthritis. The need for a simple, well-tolerated and effective solution for cartilage repair and regeneration represents one of medicine’s most challenging unmet needs. CartiHeal's flagship Agili-C™ implant represents a significant medical breakthrough. This implant has shown to promote regeneration of true hyaline cartilage and its subchondral bone, simultaneously without the use of cells, growth factors or other exogenous agents. The cell-free implant is inserted arthroscopically or via a minimally-invasive approach. |  | Series D | Feb 01, 2012 |  |
| CartiHeal | CartiHeal, a privately held medical device company headquartered in Israel, is a pioneer in the field of cartilage regeneration. Cartilage injuries affect millions of patients around the world, and characteristically cause severe pain and disability. Hyaline cartilage has a very limited ability to heal once damaged. Research indicates that injuriesto joint cartilage, if left untreated, may lead to progressive joint changes and early onset of osteoarthritis. The need for a simple, well-tolerated and effective solution for cartilage repair and regeneration represents one of medicine’s most challenging unmet needs. CartiHeal's flagship Agili-C™ implant represents a significant medical breakthrough. This implant has shown to promote regeneration of true hyaline cartilage and its subchondral bone, simultaneously without the use of cells, growth factors or other exogenous agents. The cell-free implant is inserted arthroscopically or via a minimally-invasive approach. | $695K | Series A | Apr 11, 2009 |  |

5 of 5 investments shown.

## Co-investors
- [Accelmed](https://shizune.co/investors/profile/accelmed) — VC Fund, 4 deals together
- [Elron Ventures](https://shizune.co/investors/profile/elron-electronic-industries) — VC Fund, 4 deals together
- [Johnson & Johnson Robotics and Digital Solutions](https://shizune.co/investors/profile/johnson-johnson-innovation) — VC Fund, 1 deal together
- [MedTech Innovator](https://shizune.co/investors/profile/medtechinnovator) — VC Fund, 1 deal together
- [Peregrine Ventures](https://shizune.co/investors/profile/peregrine-ventures) — VC Fund, 1 deal together

## Similar investors

### Similar industry
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [Bpifrance](https://shizune.co/investors/profile/bpifrance) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [F6 Ventures](https://shizune.co/investors/profile/flat6labs) — VC Fund
- [Oqal](https://shizune.co/investors/profile/oqal) — VC Fund
- [Alesta Yatırım](https://shizune.co/investors/profile/alesta-girisim) — VC Fund

## Featured in investor lists
- [Medical Device Investors in Israel](https://shizune.co/investors/medical-device-investors-israel)
- [Manufacturing Investors in Middle East](https://shizune.co/investors/manufacturing-investors-middle-east)
- [Manufacturing VC Funds in Middle East](https://shizune.co/investors/manufacturing-vc-funds-middle-east)
- [Manufacturing Investors in Israel](https://shizune.co/investors/manufacturing-investors-israel)
- [Manufacturing VC Funds in Israel](https://shizune.co/investors/manufacturing-vc-funds-israel)
- [Climate Investors in Middle East](https://shizune.co/investors/climate-investors-middle-east)

## FAQ

### What does Access Medical Ventures invest in?

Access Medical Ventures invests primarily in Health Care, Manufacturing and Medical Device startups, most often at Series A and Series D stage. Most of the 5 investments tracked by Shizune back companies in Israel. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Access Medical Ventures?

Public channels for Access Medical Ventures include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Access Medical Ventures?

The team at Access Medical Ventures includes Michael Tal (Partner). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co